Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by rtftech16on Mar 23, 2018 12:40pm

81 Views

Post# 27770772

RE:RE:Understand this

Its about making money not about being sincere. I bought in again at 0.495. I sold at 0.64. Initial purchase was at 0.20. There was little risk in my opnion a deal were to be announced a couple days after the initial pop, I've never personally seen that. So I sold at initial pop knowing it would go back down and re entered after I took profits. Can't hate on me for that.

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?